Poly Medicure · NSE: POLYMED · BSE: 531768

Q3 FY23 results · Oct–Dec 2022

Poly Medicure reported revenue from operations of ₹284.83 crore (up 23.7% from Q3 FY22) and net profit of ₹50.01 crore (up 44.9% from Q3 FY22) for Q3 FY23 (Oct–Dec 2022), on a consolidated basis.

Consolidated · ₹ crore
ItemQ3 FY23Q3 FY22YoYQ2 FY23QoQ
Revenue from operations284.83230.28+23.7%274.70+3.7%
Other income14.437.14+102.2%8.69+66.1%
Total income299.26237.41+26.1%283.38+5.6%
Profit before share of associates & JVs and tax66.4345.31+46.6%58.67+13.2%
Share of profit/(loss) of associates & JVs0.360.530.58
Net profit for the period50.0134.51+44.9%43.50+15.0%
EPS, basic (₹)5.213.60+44.7%4.53+15.0%
Net margin (%)17.615.015.8

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
ItemQ3 FY23Q3 FY22YoYQ2 FY23QoQ
Revenue from operations271.74220.05+23.5%263.99+2.9%
Other income14.357.17+100.2%8.71+64.8%
Total income286.09227.22+25.9%272.69+4.9%
Profit before tax64.3245.53+41.3%60.97+5.5%
Net profit for the period47.5434.21+39.0%45.22+5.1%
EPS, basic (₹)4.953.57+38.7%4.72+4.9%
Net margin (%)17.515.517.1
Consolidated
Filed with BSE
30 Jan 2023, 10:37 IST
Board meeting
28 Jan 2023
Period
01 Oct 2022 to 31 Dec 2022
Review status
Unaudited
Source
XBRL filing on BSE
Standalone
Filed with BSE
30 Jan 2023, 10:37 IST
Board meeting
28 Jan 2023
Period
01 Oct 2022 to 31 Dec 2022
Review status
Unaudited
Source
XBRL filing on BSE